{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:05:32Z","timestamp":1794110732925,"version":"4.8.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.autrev.2020.102712","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T04:24:26Z","timestamp":1605241466000},"page":"102712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["Update in immunosuppressive therapy of myasthenia gravis"],"prefix":"10.1016","volume":"20","author":[{"given":"Agustina M.","family":"Lascano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice H.","family":"Lalive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2020.102712_bb0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory Board of the Myasthenia Gravis Foundation of America","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.autrev.2020.102712_bb0010","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.1016\/j.autrev.2020.102712_bb0015","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.autrev.2020.102712_bb0020","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2020.102712_bb0025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.autrev.2020.102712_bb0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2020.102712_bb0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2020.102712_bb0040","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00019052-200110000-00006","article-title":"Myasthenia gravis: diagnostic and management dilemmas","volume":"14","author":"Palace","year":"2001","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2020.102712_bb0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"De Feo","year":"2002","journal-title":"Muscle Nerve"},{"issue":"9","key":"10.1016\/j.autrev.2020.102712_bb0050","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2020.102712_bb0055","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13023-014-0214-5","article-title":"Thymectomy for non-thymomatous myasthenia gravis: a propensity score matched study","volume":"9","author":"Barnett","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.autrev.2020.102712_bb0060","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch Neurol"},{"issue":"17","key":"10.1016\/j.autrev.2020.102712_bb0065","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/01.wnl.0000327669.75695.38","article-title":"Treatment of ocular symptoms in myasthenia gravis","volume":"71","author":"Bhanushali","year":"2008","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.autrev.2020.102712_bb0070","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: response to long-term immunosuppressive treatment","volume":"62","author":"Sommer","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.autrev.2020.102712_bb0075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.autrev.2020.102712_bb0080","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS guidelines for the treatment of ocular myasthenia","volume":"21","author":"Kerty","year":"2014","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.autrev.2020.102712_bb0085","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2020.102712_bb0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajmg.a.10817","article-title":"Is immunosuppression therapy in renal allograft recipients teratogenic? A single-center experience","volume":"116A","author":"Bar","year":"2003","journal-title":"Am J Med Genet A"},{"issue":"3","key":"10.1016\/j.autrev.2020.102712_bb0095","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.51.3.912-a","article-title":"Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil","volume":"51","author":"Hauser","year":"1998","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2020.102712_bb0100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.56.1.94","article-title":"Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases","volume":"56","author":"Chaudhry","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2020.102712_bb0105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","article-title":"Mycophenolate mofetil for myasthenia gravis: an open-label pilot study","volume":"56","author":"Ciafaloni","year":"2001","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.autrev.2020.102712_bb0110","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","article-title":"Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability","volume":"61","author":"Meriggioli","year":"2003","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.autrev.2020.102712_bb0115","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.autrev.2020.102712_bb0120","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","author":"Muscle Study G","year":"2008","journal-title":"Neurology"},{"issue":"8961","key":"10.1016\/j.autrev.2020.102712_bb0125","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(95)92534-1","volume":"345","year":"1995","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2020.102712_bb0130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.autrev.2020.102712_bb0135","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/mus.24536","article-title":"Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis","volume":"52","author":"Buzzard","year":"2015","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.autrev.2020.102712_bb0140","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00415-019-09622-4","article-title":"Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis","volume":"267","author":"Gomez-Figueroa","year":"2020","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.autrev.2020.102712_bb0145","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102712_bb0150","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.55.3.448","article-title":"Retrospective analysis of the use of cyclosporine in myasthenia gravis","volume":"55","author":"Ciafaloni","year":"2000","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.autrev.2020.102712_bb0155","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s004150050141","article-title":"Long-term cyclosporine treatment in a group of severe myasthenia gravis patients","volume":"244","author":"Bonifati","year":"1997","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.autrev.2020.102712_bb0160","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N Engl J Med"},{"issue":"5\u20136","key":"10.1016\/j.autrev.2020.102712_bb0165","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.autrev.2020.102712_bb0170","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose FK506 in the treatment of myasthenia gravis--a randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"Eur Neurol"},{"issue":"8","key":"10.1016\/j.autrev.2020.102712_bb0175","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2169\/internalmedicine.47.0513","article-title":"Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus","volume":"47","author":"Nagaishi","year":"2008","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.autrev.2020.102712_bb0180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/01.nrl.0000256352.77668.ef","article-title":"Beneficial effect of tacrolimus on myasthenia gravis with thymoma","volume":"13","author":"Mitsui","year":"2007","journal-title":"Neurologist"},{"issue":"9","key":"10.1016\/j.autrev.2020.102712_bb0185","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","article-title":"Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis","volume":"64","author":"Ponseti","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2020.102712_bb0190","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jocn.2004.12.008","article-title":"Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone","volume":"13","author":"Shimojima","year":"2006","journal-title":"J Clin Neurosci"},{"issue":"4","key":"10.1016\/j.autrev.2020.102712_bb0195","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.2005.00378.x","article-title":"Cyclosporine in the treatment of myasthenia gravis","volume":"111","author":"Lavrnic","year":"2005","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2020.102712_bb0200","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","volume":"201-202","author":"Illa","year":"2008","journal-title":"J Neuroimmunol"},{"issue":"2","key":"10.1016\/j.autrev.2020.102712_bb0205","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","article-title":"Successful treatment of refractory generalized myasthenia gravis with rituximab","volume":"16","author":"Lebrun","year":"2009","journal-title":"Eur J Neurol"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2020.102712_bb0210","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2009.02.357","article-title":"Rituximab for myasthenia gravis: three case reports and review of the literature","volume":"280","author":"Stieglbauer","year":"2009","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.autrev.2020.102712_bb0215","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis","volume":"41","author":"Zebardast","year":"2010","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.autrev.2020.102712_bb0220","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CND.0b013e31819a8403","article-title":"Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review","volume":"10","author":"Nelson","year":"2009","journal-title":"J Clin Neuromuscul Dis"},{"issue":"6","key":"10.1016\/j.autrev.2020.102712_bb0225","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","article-title":"Use and monitoring of low dose rituximab in myasthenia gravis","volume":"82","author":"Blum","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.autrev.2020.102712_bb0230","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.autrev.2020.102712_bb0235","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102712_bb0240","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mus.26876","article-title":"Rituximab in late-onset myasthenia gravis is safe and effective","volume":"62","author":"Sahai","year":"2020","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.autrev.2020.102712_bb0245","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.autrev.2020.102712_bb0250","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1002\/mus.26707","article-title":"Refractory myasthenia gravis successfully treated with ofatumumab","volume":"60","author":"Waters","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2020.102712_bb0255","article-title":"A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily evaluate safety, tolerability, pharmacokinetics and efficacy of CFZ533 in moderate to severe myasthenia gravis.","author":"Novartis Pharmaceuticals.","year":"2015","journal-title":"Clinicaltrialsgov"},{"issue":"16","key":"10.1016\/j.autrev.2020.102712_bb0260","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.autrev.2020.102712_bb0265","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","article-title":"Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab","volume":"27","author":"Jonsson","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.autrev.2020.102712_bb0270","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3233\/JND-170211","article-title":"Obinutuzumab plus chlorambucil in a patient with severe myasthenia gravis and chronic lymphocytic leukemia","volume":"4","author":"Russell","year":"2017","journal-title":"J Neuromuscul Dis"},{"issue":"12","key":"10.1016\/j.autrev.2020.102712_bb0275","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","article-title":"Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis","volume":"179","author":"Zhou","year":"2007","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2020.102712_bb0280","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/mus.25529","article-title":"QMG and MG-ADL correlations: study of eculizumab treatment of myasthenia gravis","volume":"56","author":"Howard","year":"2017","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.autrev.2020.102712_bb0285","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.autrev.2020.102712_bb0290","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2020.102712_bb0295","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor Zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, Multicenter Clinical Trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102712_bb0300","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","article-title":"Ravulizumab: first global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.autrev.2020.102712_bb0305","doi-asserted-by":"crossref","first-page":"102366","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor-targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"23","key":"10.1016\/j.autrev.2020.102712_bb0310","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.autrev.2020.102712_bb0315","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2020.102712_bb0320","first-page":"9(414)","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.autrev.2020.102712_bb0325","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.autrev.2020.102712_bb0330","article-title":"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis","author":"Momenta Pharmaceuticals","year":"2019","journal-title":"Clinicaltrialsgov"},{"key":"10.1016\/j.autrev.2020.102712_bb0335","article-title":"A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients","author":"Immunovant Sciences GmbH.","year":"2019","journal-title":"Clinicaltrialsgov"},{"key":"10.1016\/j.autrev.2020.102712_bb0340","series-title":"AAN Enterprises","article-title":"Proof-of-concept and safety of the anti-FcRn antibody rozanolixizumab in patients with moderate-to-severe generalized myasthenia gravis (GMG): A Phase 2a Study (S43. 001)","author":"Bril","year":"2019"},{"issue":"6","key":"10.1016\/j.autrev.2020.102712_bb0345","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaneurol.2016.0113","article-title":"Myasthenia gravis treated with autologous hematopoietic stem cell transplantation","volume":"73","author":"Bryant","year":"2016","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2020.102712_bb0350","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","article-title":"Measuring clinical treatment response in myasthenia gravis","volume":"36","author":"Barnett","year":"2018","journal-title":"Neurol Clin"},{"issue":"1","key":"10.1016\/j.autrev.2020.102712_bb0355","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/mus.21713","article-title":"History of outcome measures for myasthenia gravis","volume":"42","author":"Burns","year":"2010","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.autrev.2020.102712_bb0360","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2020.102712_bb0365","article-title":"Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG).","author":"Cartesian Therapeutics.","year":"2019","journal-title":"Clinicaltrialsgov"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220302913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220302913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:20:06Z","timestamp":1761600006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220302913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1568997220302913"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102712","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update in immunosuppressive therapy of myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102712"}}